4559.T लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 11:45):

Stats
आज की मात्रा	58 300.00
औसत मात्रा	59 653.00
बाजार मूल्य	93.41B
EPS	¥0 ( 2024-01-31 )
अगली कमाई की तारीख	( ¥0 ) 2024-05-09
Last Dividend	¥22.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	10.81
ATR14	¥1.494 (0.07%)

मात्रा सहसंबंध

लंबा: -0.05 (neutral)

छोटा: 0.48 (neutral)

Signal:(51.893) Neutral

Zeria Pharmaceutical Co., सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Zeria Pharmaceutical Co., सहसंबंध - मुद्रा/वस्त्र

0.23
( neutral )

0.30
( neutral )

0.72
( moderate )

0.26
( neutral )

0.43
( neutral )

-0.60
( weak negative )

Zeria Pharmaceutical Co., वित्तीय

Annual	2022
राजस्व:	¥68.38B
सकल लाभ:	¥49.49B (72.37 %)
EPS:	¥140.26

FY	2022
राजस्व:	¥68.38B
सकल लाभ:	¥49.49B (72.37 %)
EPS:	¥140.26

FY	2022
राजस्व:	¥59.53B
सकल लाभ:	¥42.15B (70.80 %)
EPS:	¥87.76

FY	2021
राजस्व:	¥55.43B
सकल लाभ:	¥39.63B (71.50 %)
EPS:	¥67.72

Financial Reports:

No articles found.

Zeria Pharmaceutical Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥18.00 (N/A)	¥0 (N/A)	¥22.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Zeria Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.56 - Stable (11.30%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥7.27	2001-03-27
Last Dividend	¥22.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	46	--
Total Paid Out	¥532.64	--
Avg. Dividend % Per Year	0.00%	--
Score	3.85	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.56
Div. Directional Score	7.95	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.85

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8369.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
7762.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6937.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6294.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
5018.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
4220.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3434.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2540.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9468.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
8097.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.116	1.500	7.68	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0564	1.200	8.12	9.74	[0 - 0.3]
returnOnEquityTTM	0.121	1.500	9.77	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.086	0.800	9.57	7.66	[1 - 3]
quickRatioTTM	0.787	0.800	-0.0759	-0.0607	[0.8 - 2.5]
cashRatioTTM	0.350	1.500	9.17	10.00	[0.2 - 2]
debtRatioTTM	0.331	-1.500	4.48	-6.73	[0 - 0.6]
interestCoverageTTM	23.81	1.000	2.29	2.29	[3 - 30]
operatingCashFlowPerShareTTM	313.62	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	313.62	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.646	-1.500	7.42	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.739	1.000	1.016	1.016	[0.2 - 0.8]
operatingProfitMarginTTM	0.133	1.000	9.33	9.33	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.273	1.000	9.60	9.60	[0.2 - 2]
assetTurnoverTTM	0.487	0.800	-0.0854	-0.0683	[0.5 - 2]
Total Score				10.34

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.81	1.000	9.01	0	[1 - 100]
returnOnEquityTTM	0.121	2.50	9.85	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	313.62	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.08	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	313.62	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.378	1.500	-0.817	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.185	1.000	7.87	0	[0.1 - 0.5]
Total Score				5.56

Zeria Pharmaceutical Co.,

Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; sclerosing agent for varicose veins; anti-inflammatory topical blood circulation enhancers; non-steroidal anti-inflammatory ophthalmic solutions; absorbable topical hemostat products; and proton pump inhibitors. In addition, it offers consumer healthcare products, such as nutritional health drugs, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, and food for specified health uses. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.

के लिए वास्तविक समय के अद्यतन Zeria Pharmaceutical Co., [4559.T]

Upcoming Earnings Alert

Zeria Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Commentary

Top 10 dividend Companies for JPX

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)